Omics-Enhanced Nanomedicine for Cancer Therapy

被引:1
作者
Qi, Lin [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Li, Zhihong [1 ,2 ]
Liu, Jianping [3 ,4 ,5 ,6 ,7 ,8 ]
Chen, Xiaoyuan [2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
机构
[1] Cent South Univ, Xiangya Hosp 2, Dept Orthoped, Changsha 410011, Hunan, Peoples R China
[2] Second Xiangya Hosp, Hunan Key Lab Tumor Models & Individualized Med, Changsha 410011, Hunan, Peoples R China
[3] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Diagnost Radiol, Singapore 119074, Singapore
[4] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Surg, Singapore 119074, Singapore
[5] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Chem & Biomol Engn, Singapore 119074, Singapore
[6] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biomed Engn, Singapore 119074, Singapore
[7] Natl Univ Singapore, Coll Design & Engn, Singapore 119074, Singapore
[8] Natl Univ Singapore, Yong Loo Lin Sch Med, Nanomed Translat Res Program, Singapore 117597, Singapore
[9] Natl Univ Singapore, Clin Imaging Res Ctr, Ctr Translat Med, Yong Loo Lin Sch Med, Singapore 117599, Singapore
[10] ASTAR, Inst Mol & Cell Biol, 61 Biopolis Dr, Singapore 138673, Singapore
[11] Natl Univ Singapore, Theranost Ctr Excellence TCE, Yong Loo Lin Sch Med, 11 Biopolis Way, Singapore 138667, Singapore
基金
新加坡国家研究基金会; 英国医学研究理事会;
关键词
cancer therapy; nanomedicine; nanomedicine-mediated biological response; nanosystem design; omics technology; SINGLE-CELL TRANSCRIPTOMICS; GUT MICROBIOTA; BIOMOLECULE CORONA; MASS-SPECTROMETRY; TUMOR; NANOPARTICLES; LIPIDOMICS; METABOLOMICS; CHEMOTHERAPY; CHALLENGES;
D O I
10.1002/adma.202409102
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Cancer nanomedicine has emerged as a promising approach to overcome the limitations of conventional cancer therapies, offering enhanced efficacy and safety in cancer management. However, the inherent heterogeneity of tumors presents increasing challenges for the application of cancer nanomedicine in both diagnosis and treatment. This heterogeneity necessitates the integration of advanced and high-throughput analytical techniques to tailor nanomedicine strategies to individual tumor profiles. Omics technologies, encompassing genomics, epigenomics, transcriptomics, proteomics, metabolomics, and more, provide unparalleled insights into the molecular and cellular mechanisms underlying cancer. By dissecting tumor heterogeneity across multiple levels, these technologies offer robust support for the development of personalized and precise cancer nanomedicine strategies. In this review, the principles, techniques, and applications of key omics technologies are summarized. Especially, the synergistic integration of omics and nanomedicine in cancer therapy is explored, focusing on enhanced diagnostic accuracy, optimized therapeutic strategies and the assessment of nanomedicine-mediated biological responses. Moreover, this review addresses current challenges and outlines future directions in the field of omics-enhanced nanomedicine. By offering valuable insights and guidance, this review aims to advance the integration of omics with nanomedicine, ultimately driving improved diagnostic and therapeutic strategies for cancer.
引用
收藏
页数:39
相关论文
共 249 条
  • [1] Omics approaches for the assessment of biological responses to nanoparticles
    Abdelkader, Yasmin
    Perez-Davalos, Luis
    LeDuc, Richard
    Zahedi, Rene P.
    Labouta, Hagar I.
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2023, 200
  • [2] Phospholipids modifications in human hepatoma cell lines (HepG2) exposed to silver and iron oxide nanoparticles
    Adeyemi, Joseph A.
    Sorgi, Carlos Arterio
    Thomazela Machado, Ana Rita
    Ogunjimi, Abayomi T.
    Araujo Gardinassi, Luiz Gustavo
    Nardini, Viviani
    Faccioli, Lucia Helena
    Greggi Antunes, Lusania Maria
    Barbosa Jr, Fernando
    [J]. ARCHIVES OF TOXICOLOGY, 2020, 94 (08) : 2625 - 2636
  • [3] Integrating Artificial Intelligence and Nanotechnology for Precision Cancer Medicine
    Adir, Omer
    Poley, Maria
    Chen, Gal
    Froim, Sahar
    Krinsky, Nitzan
    Shklover, Jeny
    Shainsky-Roitman, Janna
    Lammers, Twan
    Schroeder, Avi
    [J]. ADVANCED MATERIALS, 2020, 32 (13)
  • [4] Clinical translation of nanomedicine with integrated digital medicine and machine learning interventions
    Ahmad, Farooq
    Muhmood, Tahir
    [J]. COLLOIDS AND SURFACES B-BIOINTERFACES, 2024, 241
  • [5] Codoping Enhanced Radioluminescence of Nanoscintillators for X-ray-Activated Synergistic Cancer Therapy and Prognosis Using Metabolomics
    Ahmad, Farooq
    Wang, Xiaoyan
    Jiang, Zhao
    Yu, Xujiang
    Liu, Xinyi
    Mao, Rihua
    Chen, Xiaoyuan
    Li, Wanwan
    [J]. ACS NANO, 2019, 13 (09) : 10419 - 10433
  • [6] An extracellular vesicle-related gene expression signature identifies high-risk patients in medulloblastoma
    Albert, Thomas K.
    Interlandi, Marta
    Sill, Martin
    Graf, Monika
    Moreno, Natalia
    Menck, Kerstin
    Rohlmann, Astrid
    Melcher, Viktoria
    Korbanka, Sonja
    Hoerste, Gerd Meyer zu
    Lautwein, Tobias
    Fruehwald, Michael C.
    Krebs, Christian F.
    Holdhof, Doerthe
    Schoof, Melanie
    Bleckmann, Annalen
    Missler, Markus
    Dugas, Martin
    Schueller, Ulrich
    Jaeger, Natalie
    Pfister, Stefan M.
    Kerl, Kornelius
    [J]. NEURO-ONCOLOGY, 2021, 23 (04) : 586 - 598
  • [7] Liquid Biopsy: From Discovery to Clinical Application
    Alix-Panabieres, Catherine
    Pantel, Klaus
    [J]. CANCER DISCOVERY, 2021, 11 (04) : 858 - 873
  • [8] Single-Molecule Sequencing: Towards Clinical Applications
    Ameur, Adam
    Kloosterman, Wigard P.
    Hestand, Matthew S.
    [J]. TRENDS IN BIOTECHNOLOGY, 2019, 37 (01) : 72 - 85
  • [9] Investigating the toxic effects induced by iron oxide nanoparticles on neuroblastoma cell line: an integrative study combining cytotoxic, genotoxic and proteomic tools
    Askri, Dalel
    Cunin, Valerie
    Beal, David
    Berthier, Sylvie
    Chovelon, Benoit
    Arnaud, Josiane
    Rachidi, Walid
    Sakly, Mohsen
    Amara, Salem
    Seve, Michel
    Lehmann, Sylvia G.
    [J]. NANOTOXICOLOGY, 2019, 13 (08) : 1021 - 1040
  • [10] Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma
    Azmi, Asfar S.
    Khan, Husain Yar
    Muqbil, Irfana
    Aboukameel, Amro
    Neggers, Jasper E.
    Daelemans, Dirk
    Mahipal, Amit
    Dyson, Gregory
    Kamgar, Mandana
    Al-Hallak, Mohammad Najeeb
    Tesfaye, Anteneh
    Kim, Steve
    Shidham, Vinod
    Mohammad, Ramzi M.
    Philip, Philip A.
    [J]. CLINICAL CANCER RESEARCH, 2020, 26 (06) : 1338 - 1348